INT222961

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 22
Total Number 22
Disease Relevance 10.76
Pain Relevance 2.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (PPARA) nucleoplasm (PPARA) small molecule metabolic process (PPARA)
nucleus (PPARA) DNA binding (PPARA) lipid metabolic process (PPARA)
Anatomy Link Frequency
hepatocytes 4
thyroid 2
nucleus 2
skin 2
PPARA (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 332 99.98 Very High Very High Very High
antagonist 39 99.84 Very High Very High Very High
Kinase C 10 96.72 Very High Very High Very High
cINOD 47 93.72 High High
cytokine 20 91.20 High High
Inflammation 166 90.80 High High
COX2 80 74.12 Quite High
Multiple sclerosis 82 73.08 Quite High
Endocannabinoid 4 70.16 Quite High
aspirin 6 53.84 Quite High
Disease Link Frequency Relevance Heat
Obesity 411 100.00 Very High Very High Very High
Apoptosis 247 100.00 Very High Very High Very High
Breast Cancer 89 100.00 Very High Very High Very High
Osteogenic Sarcomas 239 99.40 Very High Very High Very High
Colon Cancer 150 99.20 Very High Very High Very High
Coronary Heart Disease 3 98.92 Very High Very High Very High
Cancer 671 98.56 Very High Very High Very High
Lung Cancer 30 98.28 Very High Very High Very High
Retinoblastoma 4 98.08 Very High Very High Very High
Hepatotoxicity 9 97.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, the G>A substitution decreases PPARA promoter affinity for the transcription factors ERR?
Negative_regulation (decreases) of PPARA Binding (affinity) of
1) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2933242 Disease Relevance 0 Pain Relevance 0
demonstrated that the reduction of cell growth by PPAR ligands is accompanied
Negative_regulation (reduction) of PPAR Binding (ligands) of
2) Confidence 0.41 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.46 Pain Relevance 0.16
The

absence of a real link between COX-2 and PPAR?

Negative_regulation (absence) of PPAR Binding (link) of
3) Confidence 0.41 Published 2008 Journal PPAR Research Section Body Doc Link PMC2234353 Disease Relevance 0.21 Pain Relevance 0.04
agonists inhibit growth and induce apoptosis in both breast tumor cells and leukemic cells, administration of PPAR?
Negative_regulation (inhibit) of PPAR Binding (administration) of associated with breast cancer, agonist and apoptosis
4) Confidence 0.38 Published 2010 Journal PPAR Research Section Body Doc Link PMC2825651 Disease Relevance 1.86 Pain Relevance 0.38
It has been demonstrated that high concentrations of thyroid hormone inhibit the ability of PPAR?
Negative_regulation (inhibit) of PPAR Binding (ability) of in thyroid
5) Confidence 0.38 Published 2010 Journal PPAR Research Section Body Doc Link PMC2825651 Disease Relevance 0.11 Pain Relevance 0.03
at the LPL gene promoter is attenuated upon complex formation of ligand-bound PPAR?
Negative_regulation (attenuated) of PPAR Binding (formation) of
6) Confidence 0.34 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.38 Pain Relevance 0.09
Our laboratory has created and tested an engineered RXR/PPAR heterodimer consist of mouse RXR?
Negative_regulation (engineered) of PPAR Binding (heterodimer) of
7) Confidence 0.34 Published 2009 Journal PPAR Research Section Body Doc Link PMC2801013 Disease Relevance 0.07 Pain Relevance 0.03
For instance, the presence of excess LXR or its ligands reduces DNA binding of PPAR?
Negative_regulation (reduces) of PPAR Binding (binding) of
8) Confidence 0.34 Published 2009 Journal PPAR Research Section Body Doc Link PMC2801013 Disease Relevance 0 Pain Relevance 0
However, our notion of the potential for PPAR?
Negative_regulation (notion) of PPAR Binding (potential) of
9) Confidence 0.33 Published 2010 Journal PPAR Research Section Body Doc Link PMC2825651 Disease Relevance 1.45 Pain Relevance 0.14
abolishes ligand binding to PPAR?
Negative_regulation (abolishes) of PPAR Binding (binding) of
10) Confidence 0.32 Published 2008 Journal PPAR Research Section Body Doc Link PMC2442903 Disease Relevance 0.33 Pain Relevance 0.03
ligands with weaker side effects such as LSN862 have been developed [33, 40], and newer PPAR?
Negative_regulation (developed) of PPAR Binding (ligands) of
11) Confidence 0.31 Published 2009 Journal PPAR Research Section Body Doc Link PMC2770108 Disease Relevance 0.72 Pain Relevance 0.19
This finding was in marked contrast to the rat counterpart of SULT2A1, which was not inducible in primary cultured rat hepatocytes following treatment with a PPAR?
Negative_regulation (cultured) of PPAR Binding (treatment) of in hepatocytes
12) Confidence 0.30 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0 Pain Relevance 0.11
This finding was in marked contrast to the rat counterpart of SULT2A1, which was not inducible in primary cultured rat hepatocytes following treatment with a PPAR?
Negative_regulation (following) of PPAR Binding (treatment) of in hepatocytes
13) Confidence 0.30 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0 Pain Relevance 0.11
-TUSC5 interactions, Tusc5 mRNA levels were compared in archived human WAT biopsy samples before and after treatment with the PPAR?
Negative_regulation (compared) of PPAR Binding (treatment) of associated with obesity
14) Confidence 0.30 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.75 Pain Relevance 0.08
Accordingly, PPAR ligands were shown to inhibit the growth of cells from different cancer lineages in vitro [18].
Negative_regulation (inhibit) of PPAR Binding (ligands) of associated with cancer
15) Confidence 0.28 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 1.40 Pain Relevance 0.39
trans-activation, blocked the interaction of PPAR?
Negative_regulation (blocked) of PPAR Binding (interaction) of
16) Confidence 0.25 Published 2008 Journal PPAR Research Section Body Doc Link PMC2423003 Disease Relevance 0 Pain Relevance 0
A wealth of preclinical data supports a role for PPAR?
Negative_regulation (supports) of PPAR Binding (role) of
17) Confidence 0.16 Published 2008 Journal PPAR Research Section Body Doc Link PMC2605846 Disease Relevance 0.63 Pain Relevance 0.23
PPAR/RXR heterodimers can competitively inhibit ER binding at specific estrogen
Negative_regulation (/) of PPAR Binding (heterodimers) of
18) Confidence 0.16 Published 2008 Journal PPAR Research Section Body Doc Link PMC2605846 Disease Relevance 0.73 Pain Relevance 0
PPAR/RXR heterodimers can competitively inhibit ER binding at specific estrogen
Negative_regulation (inhibit) of PPAR Binding (heterodimers) of
19) Confidence 0.16 Published 2008 Journal PPAR Research Section Body Doc Link PMC2605846 Disease Relevance 0.79 Pain Relevance 0
was lower in the skin of PPAR?
Negative_regulation (lower) of PPAR Binding (skin) of in skin
20) Confidence 0.16 Published 2008 Journal PPAR Research Section Body Doc Link PMC2423003 Disease Relevance 0.14 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox